Drugs / VX-210
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02669849 | Jul 2016 → Nov 2018 | spinal cord injury | Vertex Pharmaceuticals Incorporated | Terminated | Missed primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02669849 ↗ |